Piper Sandler analyst Allison Bratzel maintains Roivant Sciences (NASDAQ:ROIV) with a Overweight and raises the price target from $20 to $22.

Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 0 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 4 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.33, a high estimate of $23.00, and a l

Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.

6 analysts have shared their evaluations of Roivant Sciences (NASDAQ:ROIV) during the recent three months, expressing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 4 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Roivant Sciences, revealing an average target of $18.33, a high estimate of $23.00, and a low estimate of $15.00. Observing a 12.8% increase, the current average has

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price target.

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.32) by 40.63 percent. The company reported quarterly sales of $28.930 million which missed the analyst consensus estimate of $32.101 million by 9.88 percent. This is a 5.68 percent increase over sales of $27.376 million the same period last year.

On Wednesday, BuzzFeed Inc (NASDAQ:BZFD) shares gained after former republican Presidential candidate Vivek Ramaswamy took a 7.7% stake in BuzzFeed for about $3.2 million as per SEC filing. As per data from Benzinga Pro, BuzzFeed shares are trading on a strong session volume of 4.84 million compared to an average 100-day volume of 938.86k. Related: BuzzFeed Shares More Than Double Following $108.6M Complex Sale, Plans To Layoff 16% Staff. According to the SEC filing, Ramaswamy “will engage in a dialogue with (BuzzFeed’s) Board of Directors and/or management about numerous operational and strategic opportunities to maximize shareholder value, including a shift in the company’s strate

7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 4 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.0, with a high estimate of $23.00 and a low estimate of $15.00. Marking an incr

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price target.

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program  IMVT-1402 cleared five Investigational New Drug (IND) applications across a range of therapeutic areas and FDA divisions, including the potentially registrational trial for difficult-to-treat rheumatoid arthritis (D2T RA) expected to initiate by March 31, 2025Batoclimab pro

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call

BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE:OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ:ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms. VTAMA® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaq

The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. Organon (NYSE:OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ:ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms. VTAMA® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon's international dermatology capabilities to the U.S. BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE:OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ:ROIV) company dedicated to developing and commercializing innov

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon's international dermatology capabilities to the U.S. Organon (NYSE:OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ:ROIV) company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's novel product, VTAMA® (tap

Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD), which affects ~200,000 patients in the U.S. and Europe; PH-ILD prevalence is meaningfully greater than that of pulmonary arterial hypertension (PAH) with limited to no treatment optionsIn the Phase 1b ATMOS study, presented today at the European Respiratory Society (ERS) Congress, a single dose of inhaled mosliciguat in pulmonary hypertension (PH) patients (N=38) led to sustained, clinically meaningful mean-max reduction

Mosliciguat is a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs via once-daily administration, which may have broad applicability across the spectrum of pulmonary hypertension (PH)In the Phase 1b ATMOS study, presented today at the European Respiratory Society (ERS) Congress, a single dose of inhaled mosliciguat in PH patients (N=38) led to sustained, clinically meaningful mean peak reduction in pulmonary vascular resistance (PVR) of up to 38%, one of the highest reductions seen in PH trials to dateOnce-daily dosing via dry powder inhaler (DPI) was well tolerated, with low rates of treatment-emergent adverse events (TEAEs)The g

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs at week 12Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease (GD)Real world claims data indicates 25-30% of Graves' Disease patients per year are uncontrolled on ATDs with minimal to no existing therapeutic options representing an attractive commercial opportunity with limited competitionIND cleared with initiation of IMVT-1402 pivotal trial in GD expected by calendar yea

H.C. Wainwright & Co., LLC, a full-service investment bank dedicated to providing corporate finance, strategic advisory, and equity research coverage to public and private companies across multiple sectors and regions, is pleased to announce the following keynote speakers and Bitcoin Mining Panel as part of its 26th Annual Global Investment Conference, September 9-11, 2024 at the Lotte New York Palace Hotel. Vivek Ramaswamy, Founder, Roivant Sciences, Ltd. (NASDAQ:ROIV); Co-Founder, Strive Asset Management; Partner, QVT Financial LP; and former U.S. presidential candidate will deliver his keynote address at 4:00 p.m. Eastern Time on Monday, September 9. On Tuesday, September 10, preemin

Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00

Guggenheim initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $17.00

BofA Securities initiated coverage of Roivant Sciences with a rating of Neutral and set a new price target of $10.50

JP Morgan initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $7.00

SVB Leerink initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $6.00

Cantor Fitzgerald initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $15.00

Goldman Sachs initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $15.00

HC Wainwright & Co. initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00